Filing Details
- Accession Number:
- 0001209191-18-046622
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-08-14 16:47:06
- Reporting Period:
- 2018-08-10
- Accepted Time:
- 2018-08-14 16:47:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578251 | T. Jeffrey Walsh | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Financial | No | Yes | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-08-10 | 1,500 | $5.50 | 36,995 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-08-10 | 425 | $155.41 | 36,570 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-08-10 | 350 | $156.63 | 36,220 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-08-10 | 620 | $157.86 | 35,600 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-08-10 | 105 | $158.57 | 35,495 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-08-10 | 1,500 | $0.00 | 1,500 | $5.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 4,007 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
- The range of prices for the transaction reported on this line was $155.15 to $156.05. The average weighted price was $155.4059. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was $156.20 to $156.95. The average weighted price was $156.6293. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was $157.30 to $158.20. The average weighted price was $157.8581. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was $158.55 to $158.90. The average weighted price was $158.5667. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.
Billionaire Hedge Funds
